Iovance Biotherapeutics

IOVA

Biotech

Health Care

Country

US

Industry

Health Care

Market Cap

Small Cap

Num. Employees

503

IPO Date

Jun 20, 2008

Create Alert

IOVA

Country

US

Industry

Health Care

Biotech

Health Care

Create Alert

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 503 full-time employees. The company went IPO on 2008-06-20. The company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. The company has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The firm is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.